Xiaohui Wang

61 Jiefang West Road
Changsha, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial.

Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial.

Journal: International journal of surgery (London, England)

Published: October 27, 2025

HBV-driven expansion of CXCR6+-exhausted T cells and CXCL16+ macrophage interaction: Implications for immunotherapy in HCC.

HBV-driven expansion of CXCR6+-exhausted T cells and CXCL16+ macrophage interaction: Implications for immunotherapy in HCC.

Journal: Innovation (Cambridge (Mass.))

Published: August 31, 2025

Pathological Complete Response after Systemic Therapy and Curative Resection in Initially Unresectable Hepatocellular Carcinoma: Feasibility of a Tumor-Free with Drug-Free Strategy.

Pathological Complete Response after Systemic Therapy and Curative Resection in Initially Unresectable Hepatocellular Carcinoma: Feasibility of a Tumor-Free with Drug-Free Strategy.

Journal: Liver cancer

Published: August 06, 2025

Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study.

Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study.

Journal: International journal of surgery (London, England)

Published: July 02, 2025

Development and Validation of Nomogram to Predict Frailty for Older Patients Undergoing Abdominal Surgery.

Development and Validation of Nomogram to Predict Frailty for Older Patients Undergoing Abdominal Surgery.

Journal: Clinical interventions in aging

Published: June 09, 2025

Outcome prediction model for patients with unresectable hepatocellular carcinoma treated with targeted therapy.

Outcome prediction model for patients with unresectable hepatocellular carcinoma treated with targeted therapy.

Journal: Scientific reports

Published: December 24, 2024

ETV4/ALYREF-mediated glycolytic metabolism through PKM2 enhances resistance to ferroptosis and promotes the development of intrahepatic cholangiocarcinoma.

ETV4/ALYREF-mediated glycolytic metabolism through PKM2 enhances resistance to ferroptosis and promotes the development of intrahepatic cholangiocarcinoma.

Journal: Cancer & metabolism

Published: October 12, 2024

Analysis of characteristics of rice tillering dynamics influenced by sowing dates based on DTM.

Analysis of characteristics of rice tillering dynamics influenced by sowing dates based on DTM.

Journal: Heliyon

Published: August 27, 2024

Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching.

Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching.

Journal: La Radiologia medica

Published: August 20, 2024

Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study.

Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study.

Journal: International journal of surgery (London, England)

Published: May 22, 2024

Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.

Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.

Journal: ImmunoTargets and therapy

Published: May 12, 2024

Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.

Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.

Journal: Journal of hepatocellular carcinoma

Published: May 12, 2024

Showing 1-12 of 22

Last Updated: 09/26/2026